BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $33,851 | -72.4% | 13,380 | -27.5% | 0.00% | – |
Q2 2023 | $122,871 | -33.4% | 18,449 | +86.7% | 0.00% | – |
Q1 2023 | $184,398 | -11.3% | 9,882 | +2.1% | 0.00% | – |
Q4 2022 | $207,883 | +94.3% | 9,678 | +7.5% | 0.00% | – |
Q3 2022 | $107,000 | -6.1% | 9,000 | +3.5% | 0.00% | – |
Q2 2022 | $114,000 | -35.2% | 8,699 | +3.6% | 0.00% | – |
Q1 2022 | $176,000 | +4.1% | 8,393 | +1.0% | 0.00% | – |
Q4 2021 | $169,000 | -32.9% | 8,314 | 0.0% | 0.00% | – |
Q3 2021 | $252,000 | +98.4% | 8,314 | +91.0% | 0.00% | – |
Q2 2021 | $127,000 | -29.1% | 4,352 | +4.8% | 0.00% | – |
Q1 2021 | $179,000 | -8.2% | 4,152 | -1.7% | 0.00% | – |
Q4 2020 | $195,000 | +143.8% | 4,224 | +129.9% | 0.00% | – |
Q3 2020 | $80,000 | -31.0% | 1,837 | -15.7% | 0.00% | – |
Q2 2020 | $116,000 | +383.3% | 2,179 | +105.2% | 0.00% | – |
Q1 2020 | $24,000 | +33.3% | 1,062 | -13.7% | 0.00% | – |
Q4 2019 | $18,000 | +157.1% | 1,230 | +22.4% | 0.00% | – |
Q3 2019 | $7,000 | -36.4% | 1,005 | 0.0% | 0.00% | – |
Q2 2019 | $11,000 | – | 1,005 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |